MedTrace Logo

The Effect of Bevacizumab on Corneal Neovascularization

NCT00797303 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2011-12-02

No results posted yet for this study

Summary

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Conditions

  • Corneal Neovascularization

Interventions

DRUG

Bevacizumab

subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months

Sponsors & Collaborators

  • Instituto de Olhos de Goiania

    lead OTHER

Principal Investigators

  • Belquiz A Nassaralla, PhD · Instituto de Olhos de Goiânia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-07-31
Completion
2008-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00797303 on ClinicalTrials.gov